| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/50-1/100 | Human,Mouse,Rat |
| ICC | 1/200 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | 2-methylacyl-CoA racemase; Alpha-methylacyl-CoA racemase; AMACR; CBAS4; RACE |
| Entrez GeneID | 23600; |
| WB Predicted band size | 42kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是关于AMACR/P504S Mouse抗体的3篇代表性文献的简要列举：
---
1. **文献名称**：*Alpha-Methylacyl-CoA Racemase: A Novel Tumor Marker for Prostate Cancer*
**作者**：Jiang Z, Woda BA, Rock KL, et al.
**摘要**：该研究首次报道AMACR(P504S)作为前列腺癌特异性生物标志物的潜力，通过免疫组化分析显示其在前列腺癌组织中高表达，而在正常或良性病变中表达缺失，为前列腺癌诊断提供了新工具。
---
2. **文献名称**：*Use of Antibody P504S (AMACR) in Prostate Needle Biopsies*
**作者**：Rubin MA, Zhou M, Dhanasekaran SM, et al.
**摘要**：研究评估了AMACR/P504S抗体在前列腺穿刺活检中的应用，证实其可显著提高前列腺癌与良性增生的鉴别诊断准确性，尤其在疑难病例中具有重要临床价值。
---
3. **文献名称**：*Comparison of Monoclonal Antibody (P504S) and Polyclonal Antibody (13H4) in Detecting AMACR in Prostatic Carcinoma*
**作者**：Zhou M, Chinnaiyan AM, Kleer CG, et al.
**摘要**：通过对比两种AMACR抗体(克隆13H4和P504S)的敏感性和特异性，研究发现P504S单克隆抗体在免疫组化中表现更优，推荐其作为前列腺癌诊断的首选试剂。
---
4. **文献名称**：*AMACR Expression in Prostatic Adenocarcinoma and Other Malignancies*
**作者**：Leav I, McNeal JE, Ho SM, et al.
**摘要**：该研究探讨了AMACR在不同肿瘤中的表达谱，发现其在前列腺癌中高度特异，但在部分肾癌和结肠癌中也有表达，提示需结合其他标志物进行鉴别诊断。
---
以上文献均聚焦于AMACR/P504S抗体的生物学特性、诊断应用及技术优化，为前列腺癌病理诊断提供了关键依据。
**Background of AMACR/P504S Mouse Antibody**
The AMACR/P504S mouse antibody is a monoclonal antibody targeting alpha-methylacyl-CoA racemase (AMACR), an enzyme encoded by the *AMACR* gene and commonly referred to as P504S. AMACR plays a critical role in lipid metabolism, particularly in the β-oxidation of branched-chain fatty acids and bile acid intermediates. It functions as a racemase, converting (2R)-methylacyl-CoA esters to their (2S)-isomers for proper degradation in peroxisomes and mitochondria.
In diagnostic pathology, AMACR/P504S has gained prominence as a biomarker for prostate cancer. Overexpression of AMACR is observed in malignant prostatic tissues, including prostatic adenocarcinoma and high-grade prostatic intraepithelial neoplasia (HGPIN), but is typically absent or weak in benign glands. This specificity makes the AMACR/P504S antibody a valuable tool in immunohistochemistry (IHC) to distinguish prostate cancer from benign mimics, such as atrophy or atypical adenomatous hyperplasia. It is often used alongside basal cell markers (e.g., p63. CK34βE12) to confirm the loss of basal cells in malignancy.
The mouse-derived monoclonal antibody (clone 13H4 is common) exhibits high sensitivity and specificity for AMACR in formalin-fixed, paraffin-embedded tissues. Beyond prostate cancer, AMACR expression has also been noted in other neoplasms, including colorectal carcinoma, renal cell carcinoma, and hepatocellular carcinoma, expanding its diagnostic utility. Validation and standardization of the antibody have been critical in ensuring reliable performance across clinical laboratories, aiding in accurate tumor classification and treatment decisions.
×
